Elaina M Silveri, SLP | |
2205 N 45th St Unit A, Seattle, WA 98103-6903 | |
(206) 547-2500 | |
(206) 547-9775 |
Full Name | Elaina M Silveri |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 2205 N 45th St Unit A, Seattle, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033692371 | NPI | - | NPPES |
LL60877222 | Other | WA | STATE LICENSE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | LL60877222 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Elaina M Silveri, SLP Po Box 400, Puyallup, WA 98371-0159 Ph: (425) 903-3783 | Elaina M Silveri, SLP 2205 N 45th St Unit A, Seattle, WA 98103-6903 Ph: (206) 547-2500 |
News Archive
A bizarre disease that caused sufferers to fall into a deep ‘sleep' while still being aware of their surroundings can offer us insight into the nature of Parkinson's disease.
A cone snail toxin discovered by Melbourne researchers has proven to have great potential for easing pain and could provide an improved treatment for neuropathic pain associated with diabetes.
An in-hospital delay of appendicitis treatment beyond two days was linked to an increased likelihood of complications, including perforation and abscess formation; longer hospitalization; increased costs; and more rarely, death, according an abstract presented Saturday, Oct. 15 at the American Academy of Pediatrics (AAP) National Conference and Exhibition in Boston.
In a new international collaborative study between The Chinese University of Hong Kong and Ann & Robert H. Lurie Children's Hospital of Chicago, researchers created a machine learning algorithm that uses brain scans to predict language ability in deaf children after they receive a cochlear implant.
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.
› Verified 6 days ago
Amy L Donaldson, PH.D., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: University Of Washington Autism Ctr, Box 357920, Seattle, WA 98195 Phone: 206-897-1801 | |
Ms. Carol L Ray, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4507 Sunnyside Ave N, Unit D, Seattle, WA 98103 Phone: 206-849-3937 | |
Ms. Linda E Eblen, MA Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4800 Sand Point Way Ne, Mail Stop W-6839, Seattle, WA 98105 Phone: 206-987-6164 | |
Mrs. Genevieve Houdet-cote, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1100 9th Ave, Ms:h4-pmr, Seattle, WA 98101 Phone: 206-341-0461 | |
Daelene King, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9100 5th Ave Ne, Seattle, WA 98115 Phone: 206-526-2662 | |
Molly Beier, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-744-3000 | |
Vassalo Speech And Language Llc Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2300 W Bertona St, Seattle, WA 98199 Phone: 978-444-0321 |